Polaryx Therapeutics, Inc. (PLYX)
NASDAQ:PLYX
PLYX Stock Chart & Stats
$2.41
$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range$2.01 - $48.91
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
$114.10M
Enterprise Value$106.28M
Total Cash (Recent Filing)$5.14M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-2.61
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding47,343,296
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio-9.82
Price to Book (P/B)362.98
Price to Sales (P/S)0.00
P/FCF Ratio-420.14
Enterprise Value/Market Cap0.93
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-13.32
Forecast
1Y Price Target
$10.00Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Polaryx Therapeutics, Inc. News
PLYX FAQ
What was Polaryx Therapeutics, Inc.’s price range in the past 12 months?
Polaryx Therapeutics, Inc. lowest stock price was $2.01 and its highest was $48.91 in the past 12 months.
What is Polaryx Therapeutics, Inc.’s market cap?
Polaryx Therapeutics, Inc.’s market cap is $114.10M.
When is Polaryx Therapeutics, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Polaryx Therapeutics, Inc.’s earnings last quarter?
Currently, no data Available
Is Polaryx Therapeutics, Inc. overvalued?
According to Wall Street analysts Polaryx Therapeutics, Inc.’s price is currently Undervalued.
Does Polaryx Therapeutics, Inc. pay dividends?
Polaryx Therapeutics, Inc. does not currently pay dividends.
What is Polaryx Therapeutics, Inc.’s EPS estimate?
Polaryx Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Polaryx Therapeutics, Inc. have?
Polaryx Therapeutics, Inc. has 47,343,296 shares outstanding.
What happened to Polaryx Therapeutics, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Polaryx Therapeutics, Inc.?
Currently, no hedge funds are holding shares in PLYX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Polaryx Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (― Downside)
$10.00 (― Downside)
Blogger Sentiment
Bullish
PLYX Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $360.0K over
the Last 3 Months
the Last 3 Months
Fundamentals
Return on Equity
-166.07%
Trailing 12-Months
Asset Growth
-21.09%
Trailing 12-Months
Company Description
Polaryx Therapeutics, Inc.
Polaryx Therapeutics, Inc. functions as a biotechnology firm dedicated to advancing small-molecule therapies for lysosomal storage and neurodegenerative conditions. Its developmental pipeline includes a trio of promising candidates: PLX-100, which combines PLX-200 with an ancillary supplement, targeting late infantile neuronal ceroid lipofuscinosis (LINCL) and related forms of NCL. PLX-200, a repurposed compound already utilized to address various diseases in both adult and pediatric populations. And PLX-300, derived from an edible plant, which works by activating PPARa to enhance the production of transcription factor EB. The company, established in 2014, maintains its base of operations in Paramus, New Jersey.
PLYX Stock 12 Month Forecast
Average Price Target
$10.00
Ownership Overview
Options Prices
Currently, No data available
---